The New Era of COVID-19: The Rise of Telehealth, Trends to Home Dialysis, and the “New Normal”
Authors: Charisse Pearson Bey, Tucker Hurtado, and Jennifer Robinson BACKGROUND: The objective of this study was to evaluate the impact of the COVID-19 pandemic to help conceptualize how patient care delivery, pharmaceutical representative interactions, conferences, and dialysis care may evolve. METHODS: Data was conducted between March 20, 2020 – March 31, 2021, providing coverage […]
Suboptimal Treatment of Anemia in CKD Non-Dialysis Patients: What Role Will HIF-PH Inhibitors Play?
Authors: Meghan Staudt, Tucker Hurtado, Jennifer Robinson BACKGROUND: The purpose of this study was to understand the real-world patient presentation and treatment priorities for CKD non-dialysis patients, focusing on the treatment of anemia of CKD. METHODS: Using a HIPAA-compliant, online chart audit tool, nephrologists (n=183) submitted de-identified clinical and non-clinical demographic information for 1,030 […]
New Drugs and Evolving Treatment Patterns in Lupus Nephritis: How Nephrologists and Rheumatologists Are Responding Differently to New Treatment Options
Authors: Ryan Rex, Tucker Hurtado, and Jennifer Robinson BACKGROUND: Early uptake and experience with recently approved lupus nephritis (LN) drugs belimumab and voclosporin reveal different perceptions, comfort levels, and prescribing intentions between nephrologists and rheumatologists. METHODS: Data were collected over four waves of research between February and May 2021 via online surveys with 50 […]
Comparing and Contrasting Glomerular Disease Patients: A Real World Analysis Showing Demographic, Clinical, and Treatment Differences Across More Than 1,000 Patients
Authors: Ryan Rex, Tucker Hurtado, and Jennifer Robinson BACKGROUND: One-half of nephrologists selected glomerular diseases as their leading area of interest in nephrology in 2020. These rare and often-idiopathic disorders are seen as particularly challenging to manage, but an influx of promising pipeline drugs may offer new treatment options in the not-so-distant future. METHODS: […]
SGLT2 Inhibitors: Will They Change the Face of Kidney Care?
Authors: Meghan Staudt, Tucker Hurtado, and Jennifer Robinson BACKGROUND: This research examines the evolving care and treatment of patients with chronic kidney disease (CKD) and type 2 diabetes (T2D), including the introduction and adoption of SGLT2 inhibitors. It includes trending on perceptions across specialists. METHODS: A total of 1,030 CKD non-dialysis patient records were […]
An Itch to Scratch: The Problem with Pruritus
Authors: Skylar Malone, Tucker Hurtado, and Jennifer Robinson BACKGROUND: Dialysis patients often suffer from some level of associated pruritus and nephrologists generally recognize the condition’s impact on patient lives, rating pruritus as a high unmet need for new therapeutic options. However, official diagnosis of CKD-associated pruritus and physician-reported estimates may be highly underestimated. METHODS: […]
Spherix Global Insights Releases the Titles of Seven Abstracts To Be Presented at American Society of Nephrology Kidney Week 2021
Independently funded research on glomerular diseases, lupus nephritis, SGLT2 inhibitors, disparities in care, HIF-PH inhibitors, CKD-associated pruritus, and COVID-19 impacts showcased in Spherix abstracts and poster presentations EXTON, Pa., November 1, 2021 /PRNewswire/ — Spherix Global Insights, a leading market intelligence firm specializing in nephrology, is excited to announce the titles of seven abstracts that will […]
Spherix Global Insights Expands Expert Coverage of IgA Nephropathy Into EU Markets and Announces Upcoming Second Annual US Patient Audit
New research provides insight into unmet needs, current treatment paradigms, and nephrologists’ opinions on upcoming pipeline product potential across the UK, Germany, France, Italy, and Spain EXTON, Pa., October 28 , 2021 /PRNewswire/ — Spherix Global Insights, a leading market intelligence firm specializing in nephrology-based research and insights, announced this month the release of Market Dynamix™: IgA […]
Ardelyx Slashes One-Third of its Workforce After FDA Rejection for Key Kidney Disease Prospect
From: FiercePharma By: Fraiser Kansteiner In the aftermath of a surprise FDA rejection in chronic kidney disease, Ardelyx is tightening its belt. Under the restructuring plan, which kicked off Monday and is expected to wrap up this month, the biotech will part ways with 33% of its workforce, or about 83 employees. Ardelyx expects […]
‘Erratic’ FDA and Inconsistent Drug Decisions Put Doctors Off New Meds: Survey
From: FiercePharma By: Beth Snyder Bulik Stunning reversals, surprise delays and controversial approvals are the order of the day at the FDA lately—and doctors have had enough. Physicians’ trust in the agency is plummeting, according to a recent survey by Spherix Global Insights. More than 40% of the doctors surveyed said their confidence in […]
